https://www.selleckchem.com/pr....oducts/VX-680(MK-045
We evaluated the relation between baseline and new-onset atrial fibrillation (AF) and outcomes, and assessed whether vericiguat modified the likelihood of new-onset AF in patients with worsening heart failure (HF) with reduced ejection fraction in VICTORIA. Of 5050 patients randomized, 5010 with recorded AF status at baseline were analysed. Patients were classified into three groups no known AF (n=2661, 53%), history of AF alone (n=992, 20%), and AF on randomization electrocardiogram (n=1357, 27%). Compared with those with no AF
Like
Comment
Share
